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A B S T R A C T
Receiving a doctor’s advice to quit smoking is an important predictor for improving smokers’ intentions to quit
smoking and successful smoking cessation. We examined reports of smokers with Crohn’s Disease (CD) and
Ulcerative Colitis (UC) regarding receiving a doctor’s advice to quit smoking in the past 12 months, and eval-
uated the differences in the rates of receiving the advice between the CD and UC patients. The data were
retrospectively reported by CD and UC patients (n = 453) who self-identified as current smokers in online
assessments conducted by IBD Partners in the period from 2011 to 2014 in the USA. Statistical methods included
chi-square tests and a multiple logistic regression model for the logit of the probability of receiving the advice as
a function of patient’s characteristics and assessment year. Overall, about 77% of smokers reported receiving a
doctor’s advice to quit smoking. The percentage was significantly (p < 0.001) higher among smokers with CD
(80%) than it was among smokers with UC (63%). While the specific differences by CD/UC depended on
smoking initiation age, the overall effect of disease type on the odds of receiving the advice remained significant:
the odds of receiving the advice were higher for smokers with CD relative to smokers with UC (OR = 3.6,
p < 0.001). Although the majority of CD and UC patients report receiving a doctor’s advice to quit smoking, the
encountered difference associated with the disease type is concerning. Because long-term smoking increases
cancer and mortality risks, doctors should address smoking cessation with all patients who smoke.
1. Introduction
While the scientific findings regarding the harmful effect of smoking
on Crohn’s Disease (CD) development and progression are consistent
(Somerville et al., 1984), there is an ongoing debate regarding the re-
lationship between smoking and Ulcerative Colitis (UC) (Berkowitz
et al., 2018; Mahid et al., 2006). The debate began several decades ago
when results from multiple published studies pointed to a possible
protective effect of smoking on UC development and disease activity
(Harries et al., 1982; Jick and Walker, 1983). Although epigenetic re-
search has been conducted with the goal of explaining the pathways
through which nicotine and its metabolites could influence UC, the
relationship between smoking and UC is not yet well understood
(Berkowitz et al., 2018). Nonetheless, there is evidence that smoking is
associated with medication nonadherence, which can worsen the dis-
ease course among IBD patients, e.g., among patients with quiescent UC
medication nonadherence is associated with increased risk of clinical
recurrence of disease (Kane et al., 2003).
The current clinical practice guidelines on treating tobacco use in
the U.S. state that all clinicians should recommend smoking cessation to
their patients who smoke (Fiore et al., 2008). A recommendation to
clinicians that smoking cessation should be an important part of IBD
patient care has been mentioned in the scientific literature (Spence
et al., 2017). The clinical guidelines on management of CD in adult
patients state “Cigarette smoking exacerbates disease activity and ac-
celerates disease recurrence and should be avoided. Active smoking
cessation programs should be encouraged” and label this as a strong
recommendation (but with a low level of evidence) (Lichtenstein et al.,
2018). Smoking cessation is also recommended as part of postoperative
care for CD patients (Lichtenstein et al., 2018). Similar recommenda-
tions are stated by the British Society for Gastroenterology (Lamb et al.,
2019). However, our search for “smoking” in the American College of
Gastroenterology clinical guideline on management of UC identified no
specific recommendations related to smoking cessation; smoking
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cessation was only mentioned in two statements: “Potential precipitants
of UC may include recent smoking cessation…” and “Evaluation of UC
during relapses should include assessment of the severity of symptoms
and potential triggers, including … recent smoking cessation” (Rubin
et al., 2019). The British Society for Gastroenterology states that “Ul-
cerative Colitis patients who continue to smoke cigarettes should be
encouraged to stop” but labels this as a weak recommendation (with a
very low level of evidence) (Lamb et al., 2019). Nonetheless, several
scientific papers suggested that because health risks of smoking out-
weigh any potential benefits, doctors should recommend smoking ces-
sation to UC patients who smoke (Bastida and Beltrán, 2011; Blackwell
et al., 2019).
We believe that the ongoing debate regarding the relationship be-
tween smoking and UC and lack of explicit recommendations to clin-
icians to advise smokers with UC to quit smoking could be confusing to
both patients and doctors. This confusion can affect doctor-patient
communications about smoking cessation, causing doctors and patients
to put aside these important discussions, which may “promote” harmful
tobacco use among smokers with IBD. Moreover, while the percentage
of receiving a doctor’s advice to quit was addressed for patients with a
chronic condition for a number of conditions, e.g., asthma, anxiety,
coronary heart disease and depression (Keith et al., 2017), we could not
locate any estimates for patients with CD and UC.
In this study, we examined reports of smokers with CD and UC re-
garding receiving a doctor’s advice to quit smoking in the past
12 months. The study aim was to determine if receiving a doctor’s
advice to quit smoking is associated with the IBD-related factors in-
cluding disease type (CD, UC), having a primary care physician (PCP),
having a gastroenterologist (GE), and ever having bowel surgery.
2. Materials and methods
2.1. Data and measures
In this study, we used a de-identified dataset provided by IBD
Partners, formerly known as the Crohn’s and Colitis Foundation of
America Partners, which is one of the largest IBD research networks in
the world (IBD, 2020). The network is supported by the Crohn’s and
Colitis Foundation and the University of North Carolina School of
Medicine, and enables bringing together researchers and IBD patients.
As of early 2019, the network comprised 15,680 IBD patients and more
than 300 researchers. IBD patients who are the members of the network
participate in online assessments twice a year. The assessments include
items related to demographic characteristics, IBD and treatment (e.g.,
disease type, severity and activity, complications, and medications)
(IBD, 2020). In this study, we used data from the baseline assessments
conducted during the period from June 2011 to February 2014. We
considered reports of only those patients (n = 453) who:
1. Reported initiating smoking more than a year prior to the assess-
ment, i.e., the difference between the age at the assessment and
smoking initiation age (in years) was more than one year;
2. Reported being a current smoker at the time of the assessment, i.e.,
answered “Yes” to both survey items: “Have you smoked at least 100
cigarettes in your life?” and “Do you currently smoke cigarettes?”;
3. Responded either “Yes” or “No” to the survey item, “In the past year
have you been advised by your doctor to quit smoking or has your
doctor offered you cessation medications, methods or strategies to
quit smoking?” We used “Yes” and “No” responses to this question
to define the primary (binary) measure – receiving a doctor’s advice
to quit smoking;
4. Were diagnosed with CD or UC at least one year prior to the as-
sessment; and
5. Completed all items related to study measures (see Table 1).
The explanatory measures included sociodemographic
characteristics, smoking initiation age, IBD-related factors and assess-
ment year (listed in Table 1).
2.2. Statistical analysis
The significance level was 5%. Significance of associations was as-
sessed using chi-square (CS) tests and a multiple logistic regression
model, where the logit of the probability of receiving a doctor’s advice
to quit was modeled as a function of all explanatory measures depicted
in Table 1. Significance of all two-way interactions for factors with
sufficient subgroup sizes was examined using backward elimination
with 5% level for removal. Bonferroni adjustments for multiplicity were
used to adjust the original p-values; pa denotes the adjusted p-value.
Statistical computing was performed using SAS®9.4 (SAS, 2016).
3. Results
About 76.6% (95%CI = 72.7%−80.5%; n = 347) of smokers re-
ported receiving a doctor’s advice to quit smoking. Receiving this ad-
vice was significantly associated with the disease type (p < 0.001) and
ever having bowel surgery (p = 0.026). The percentage of patients who
reported receiving advice to quit was significantly higher among smo-
kers with CD (80.2%) than among smokers with UC (62.8%). In addi-
tion, the percentage was significantly higher among smokers who have
had a bowel surgery (81.5%) than those who have not (72.6%). Having
a PCP (77.5% versus 67.5%) and having a GE (77.5% versus 66.7%)
were associated with higher percentage of receiving advice to quit but
not statistically significantly.
The model (Likelihood Ratio CS = 48.2, df = 20, p < 0.001; the
percentage of concordant predicted and observed cases was 69.1%)
included the interactions between disease type and smoking initiation
age (p = 0.042), and age and sex (p = 0.006). Disease type
(p < 0.001) and age (p = 0.026) were the only significant main effects
in the model (see Table 1 for all main effects). After adjustments for
multiplicity, only one comparison was significant that is, among pa-
tients who initiated smoking when they were 19 years old or older, the
odds of receiving a doctor’s advice to quit were significantly higher
among CD relative to UC patients (OR = 7.4, pa = 0.003,
97.5%CI = 1.8:30.5; p = 0.002, 95%CI = 2.1:22.5). Among patients
who initiated smoking when they were 18 years old or younger, the
odds of receiving a doctor’s advice to quit were higher among CD re-
lative to UC patients but the odds ratio was not significant (OR = 1.8,
pa = 0.166, 97.5%CI = 0.8:3.7; p = 0.083, 95%CI = 0.9:3.4). Fig. 1
presents the odds of receiving a doctor’s advice to quit smoking for four
subgroups of smokers (disease type × smoking initiation age) and il-
lustrates the findings regarding the odds ratios discussed above. Fig. 1
shows that among four subgroups of patients, the highest odds (2.2) of
receiving a doctor’s advice to quit smoking corresponded to CD patients
who started smoking at the age of 19 years or older and the lowest odds
(0.3) corresponded to UC patients who started smoking at the age of
19 years or older. The overall effect of the disease type was consistent
with the one based on a CS test: the odds of receiving a doctor’s advice
to quit were significantly higher among CD patients than they were
among UC patients (OR = 3.6, 95%CI = 1.8:7.4, overall effect
p < 0.001). One additional (secondary) finding was that among
18–30 year-old patients, the odds of receiving a doctor’s advice to quit
were significantly higher among women than they were among men
(OR = 8.1, pa = 0.011, 98.75%CI = 1.4:46.6; p = 0.003,
95%CI = 2.1:32.0); this finding is not further discussed.
4. Conclusions
The majority of smokers with IBD (77%) reported receiving a doc-
tor’s advice to quit smoking in the past 12 months (prior to the as-
sessment in 2011–2014). However, we observed lower percentages for
smokers with CD (81%) and smokers with UC (65%) than the
J.N. Soulakova, et al. Preventive Medicine Reports 18 (2020) 101091
2
2012–2014 percentages estimated for a number of chronic conditions
that ranged from 83% for smokers with substance abuse to 94% for
smokers with heart disease (Keith et al., 2017). Moreover, the percen-
tage of smokers reporting that they received the advice was con-
siderably higher among smokers with CD relative to smokers with UC.
While the magnitude of the difference depended on the patient’s
smoking initiation age, the overall effect was consistently significant in
analyses that adjusted and did not adjust for other factors. There could
be several potential reasons for the difference associated with disease
type. First, smokers with UC could be less open about their smoking
behaviors relative to CD patients. It has been shown that the percentage
of patients who are aware of the adverse effect of smoking was much
Table 1
Patients’ Characteristics of Adults Diagnosed with CD and UC, and Assessment Year (n = 453); Data Were Provided by IBD Partners (2011–2014, USA).
Characteristic Group CD Patients (n = 359) UC Patients (n = 94) Overall (N = 453)
Age 18–30 years old 15.0% 17.0% 15.5%
31–45 years old 33.4% 38.3% 34.4%
46–55 years old 29.0% 21.3% 27.4%
56 + years old 22.6% 23.4% 22.7%
Sex Male 22.3% 25.5% 23.0%
Female 77.7% 74.5% 77.0%
Race/Ethnicity Non-Hispanic white 93.0% 94.7% 93.4%
Othera 7.0% 5.3% 6.6%
Educational Attainment Lower educated (High school or below) 15.9% 10.6% 14.8%
Higher educated (above High school) 84.1% 89.4% 85.2%
Region of Residence Midwest 26.5% 19.2% 24.9%
Northeast 26.5% 25.5% 26.3%
South 31.5% 38.3% 32.9%
West 15.6% 17.0% 15.9%
Smoking Initiation Age ≤18 years old 79.4% 80.9% 79.7%
≥19 years old 20.6% 19.2% 20.3%
Having a Primary Care Physician Yes 90.3% 94.7% 91.2%
No 9.8% 5.3% 8.8%
Having a Gastroenterologist Yes 93.0% 88.3% 92.1%
No 7.0% 11.7% 7.9%
Ever Having a Bowel Surgery Yes 55.4% 6.4% 45.3%
No 44.6% 93.6% 54.8%
Assessment Year 2011 67.4% 64.9% 66.9%
2012 25.9% 24.5% 25.6%
2013–14b 6.7% 10.6% 7.5%
a The “other” racial/ethnic category includes 9 (2.0%) non-Hispanic (NH) Black/African American, 9 (2.0%) NH Multiracial, 8 (1.8%) NH other and 4 (0.8%)
Hispanic patients.
b There were 31 (6.8%) patients who completed the assessment in 2013 and only 3 (0.7%) patients who completed the assessment in 2014.
Fig. 1. Odds of Receiving a Doctor’s Advice to Quit Smoking and 95% Wald Confidence Intervals by Disease Type and Smoking Initiation Age (SIA) Subgroups; Data
Were Provided by IBD Partners (2011–2014, USA).
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smaller among UC patients (13.0%) than CD patients (57.7%)
(Ducharme-Bénard et al., 2016), therefore, UC patients who smoke
might be more prone to not disclosing their smoking behaviors (relative
to CD patients) during doctor-patient communication. Second, health-
care professionals could be less enthusiastic about discussing smoking
cessation with UC patients than CD patients because smoking cessation
recommendations are labeled as “weak recommendations’ for UC pa-
tients in the clinical guidelines (Lamb et al., 2019; Rubin et al., 2019).
These two reasons (which could coincide) would be consistent with
ongoing debates regarding the effects of smoking on UC and the lack of
explicit clinical recommendations for smoking cessation among UC
patients.
The key limitation of this study is that the data were collected via a
convenience sample and thus the studied sample might be not re-
presentative (in terms of studied characteristics) of the target popula-
tion – adult smokers with IBD in the U.S.—possibly affecting the results.
Likewise, limiting to patients with complete information on all study
measures could have introduced an additional bias if the missing in-
formation is not “missing completely at random”. In addition, the
Reviewers pointed that measures defined in a different way, e.g.,
smoking initiation age with split at 21 years of age instead of the
considered split at 18 years of age, could result in different findings.
Likewise, inclusion of other measures in the model, e.g., total number of
years smoked (not available in this study), could potentially lead to
other findings. An additional limitation pertains to small sample sizes
for some time periods studied, prohibiting estimation of potential over-
time changes. Moreover, because the vast majority of reports were
made in 2011–2012 (92.5%), the results are expected to be more ac-
curate for 2011–2012 (rather than 2010–2014). Finally, the data could
be subject to response bias, e.g., due to respondent’s lack of interest in
the information requested or pain, that could result in inaccurate re-
ports of smoking-related information (Tourangeau et al., 2000; Bright
and Soulakova, 2015; Soulakova and Crockett, 2014).
Future research should incorporate both, medical records and pa-
tients’ reports, to confirm that the patients’ reports of receiving a
doctor’ advice in the past 12 months are accurate (overall), and assess
the potential discrepancies in the rates of receiving a doctor’s advice to
quit for CD and UC patients. This knowledge will help advance doctor-
patient communications with the primary goal of improving patient’s
quality of life and health-related outcomes.
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